Details for Patent: 8,377,903

Which drugs does patent 8,377,903 protect, and when does it expire?

Patent 8,377,903 protects MAVENCLAD and is included in one NDA.

This patent has sixty-nine patent family members in thirty countries.

Summary for Patent: 8,377,903

Title:	Cladribine regimen for treating multiple sclerosis
Abstract:	The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be the orally administered and wherein re-treatments are possible.
Inventor(s):	De Luca; Giampiero (Conches/Geneva, CH), Ythier; Arnaud (Collex-Bossy, CH), Munafo; Alain (Tartegnin, CH), Lopez-Bresnahan; Maria (Lincoln, MA)
Assignee:	Merck Serono SA (Coinsins, Vaud, CH)
Application Number:	12/766,173
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,377,903
Patent Claim Types: see list of patent claims	Use; Formulation; Delivery; Dosage form;

Drugs Protected by US Patent 8,377,903

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Emd Serono Inc	MAVENCLAD	cladribine	TABLET;ORAL	022561-001	Mar 29, 2019		RX	Yes	Yes						TREATING RRMS OR SPMS WITH ORAL CLADRIBINE: (I) 2-4 MONTHS INDUCTION WITH 1.7 MG/KG - 3.5 MG/KG CLADRIBINE; (II) CLADRIBINE-FREE PERIOD OF ABOUT 8-10 MONTHS; (III) 2-4 MONTHS MAINTENANCE WITH ABOUT 1.7 MG/KG CLADRIBINE; (IV) CLADRIBINE-FREE PERIOD

Foreign Priority and PCT Information for Patent: 8,377,903

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	04106909	Dec 22, 2004

International Family Members for US Patent 8,377,903

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	052830
Argentina	106246
Austria	E547106